Soluble E-cadherin as a serum biomarker in patients with HBV-related liver diseases

Clin Biochem. 2016 Nov;49(16-17):1232-1237. doi: 10.1016/j.clinbiochem.2016.07.011. Epub 2016 Jul 22.

Abstract

Objective: Substantial evidence indicates that serum sE-cadherin is a pivotal regulator that contributes to the initiation and development of various types of diseases. However, very little is known about the relationship between levels of serum sE-cadherin and HBV-related disorders. The overall goal of the study is to get a better insight into whether or not serum sE-cadherin is involved in HBV-related diseases.

Design and methods: Serum levels of sE-cadherin and IFN-γ, from 113 patients with chronic hepatitis B, 101 patients with HBV-related cirrhosis, 75 patients with hepatocellular carcinoma and 125 healthy individuals were measured with commercial available sandwich ELISA kits.

Results: sE-cadherin values were significantly higher in patients compared to healthy control (p<0.0001). The levels of serum sE-cadherin were significantly positively correlated with the serum levels of IFN-γ, alanine transaminase and aspartate aminotransferase in chronic hepatitis B and cirrhosis patients. In hepatocellular carcinoma patients, serum sE-cadherin concentrations were only significantly positively correlated with the serum levels of ALT and AST.

Conclusions: Serum sE-cadherin levels maybe an important indicator of the pathogenesis of progression of HBV-related disorders.

Keywords: Chronic hepatitis B; Cirrhosis; Cytokine; Hepatitis B virus; Hepatocellular carcinoma; sE-cadherin.

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / blood*
  • Cadherins / blood*
  • Female
  • Hepatitis B / blood*
  • Hepatitis B virus / pathogenicity*
  • Humans
  • Interferon-gamma / blood
  • Male
  • Middle Aged
  • Young Adult

Substances

  • Biomarkers
  • Cadherins
  • Interferon-gamma